According to a new study involving treatment for diabetes, which has led to significant weight loss for an average participant, help for obesity can appear in a pill.
A medical treatment for obesity that leads to 10% weight loss in the majority and 20% weight loss in over a third of participants. This is the beginning of a new era, “said Rachel Batterham, one of the researchers involved in the study and professor of obesity, diabetes and endocrinology and head of the UCL Center for Obesity Research and the UCLH Center for Weight Management. Twitter
TWTR,
A total of 1,961 adults from North America, South America, Asia and Europe participated in the 2018 68-week study involving the drug semaglutide, which is an antidiabetic drug used to treat type 2 diabetes, according to the study. published Wednesday in The New England Journal of Medicine
People received a weekly injection of semaglutide or placebo, along with counseling sessions to adhere to a low-calorie diet and increased exercise. Semaglutide is sold under the names Ozempic and Rybelsus by the Danish drug company Novo Nordisk NVO,
Participants who received semaglutide were more likely to lose 5% or more, 10% or more, 15% or more, and 20% or more of their initial body weight at week 68 than those who received placebo. said the study.
Study participants were 18 years of age and older, with one or more previous dietary attempts to lose weight, and a body mass index (BMI) of 30 or higher or a BMI of 27 or more. many weight-related conditions, treated or untreated. A normal BMI tends to fall between 18.5 and 24.9.
“Our study showed that in adults with overweight or obesity (without diabetes), subcutaneous semaglutidial intervention once a week plus lifestyle intervention was associated with a substantial, sustained, clinically relevant loss, of 14.9%, 86% of the participants achieving at least 5% weight loss “, said the researchers of the study.
Novo Nordisk presented semaglutide as a weight management treatment for regulatory approval to the Food and Drug Administration and the European Medicines Agency.